Changes in HIV Viral Load in Patients Undergoing Treatment for Filariasis
Filarial Infection, HIV Infections
About this trial
This is an observational trial for Filarial Infection focused on measuring Coinfection, AIDS, Lymphatic Filariasis, Diethylcarbamazine (DEC), Albendazole
Eligibility Criteria
INCLUSION CRITERIA: Greater than 18 years of age. Ability to give informed consent HIV positive If on antiretrovirals or treatment for opportunistic infections, have it be a stable maintenance period of at least 2 months Male or female, providing women are neither pregnant nor breast-feeding Willingness to adhere to the testing schedule of the protocol and to provide small amounts of blood (5 ml) on multiple occasions Willingness to be treated with DEC/albendazole Willingness, if female, to be tested for pregnancy and to be informed of the test result Willingness to have samples stored for future research EXCLUSION CRITERIA: Acutely ill at the time of enrollment into the study i.e. newly diagnosed with an opportunistic infection and not yet stabilized on a treatment regime. Hemoglobin less than 9 g/l for women and less than 10 g/l for men AST, ALT greater than 5 times normal Evidence of acute HIV infection (acute antiretroviral syndrome) Active tuberculosis or known tuberculosis A true allergy to DEC or albendazole At the discretion of the investigator if it is felt that someone is not appropriate for the study (i.e. known active drug use, patient with history of chronic noncompliance in clinic visits)
Sites / Locations
- Government General Hospital
- Tuberculosis Research Centre
- YRG Care